TLR8 activated by aPLs induces an increment in type I IFNs in antiphospholipid syndrome (APS) [98], and this mechanism can participate in the aberrant type I IFN signaling and thrombo-inflammation present in severe COVID-19 patients [99]. The gene discussed is TLR8; the disease is COVID-19.